Amendment No. 1 to the Form 8-K filed 12/12/2005

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K/A

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): December 12, 2005

 

 

GILEAD SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

 

DELAWARE   0-19731   94-3047598

(State or other jurisdiction of

incorporation or organization)

   (Commission File Number)  

(I.R.S. Employer

Identification No.)

 

333 LAKESIDE DRIVE, FOSTER CITY, CALIFORNIA

(Address of principal executive offices)

 

94404

(Zip Code)

 

(650) 574-3000

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Explanatory Note

 

Gilead Sciences, Inc. is filing this amendment to its Current Report on Form 8-K, filed with the Securities and Exchange Commission on December 12, 2005, to disclose Mr. Madigan’s appointment to certain committees of the Board of Directors of Gilead Sciences, Inc.

 

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

 

On December 12, 2005, Gilead Sciences, Inc. filed a Current Report on Form 8-K to report that John W. Madigan had been appointed to serve on Gilead’s Board of Directors. At the time of his appointment, the Board of Directors had not yet determined the committees on which Mr. Madigan would serve.

 

On January 26, 2006, the Board of Directors appointed Mr. Madigan to serve on the Audit Committee and the Compensation Committee of the Board of Directors.

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    GILEAD SCIENCES, INC.
Dated: January 31, 2006   By:  

/s/ John F. Milligan

        John F. Milligan
       

Executive Vice President and

Chief Financial Officer